Design, Synthesis and biochemical evaluation of novel anthracenes, ethanoanthracenes and related compounds to target Burkitt's Lymphoma
Citation:Andrew J. Byrne, 'Design, Synthesis and biochemical evaluation of novel anthracenes, ethanoanthracenes and related compounds to target Burkitt's Lymphoma', [thesis], Trinity College (Dublin, Ireland). School of Pharmacy & Pharmaceutical Sciences, 2015, pp 466
Byrne TCD THESIS 11064 Design Synthesis.pdf (PDF) 219.5Mb
Burkitt's lymphoma is an aggressive non-Hodgkin lymphoma occurring with high incidence in developing areas such as equatorial Africa and Papua New Guinea. Within these tropical regions of high incidence (40-50 per 10 6), Burkitt's lymphoma accounts for approximately 50% of childhood cancers and up to 90% of childhood lymphomas diagnosed. The treatment of Burkitt's lymphoma in these regions is insufficient and the development of new, safe and cost effective therapeutics are of current interest. Previous work within the Meegan and Williams groups in Trinity College Dublin identified a potent apoptotic effect induced by the (E)-1,3-bis(aryl)-2-nitro-1-propenes and the tetracyclic antidepressant maprotiline in Burkitt's lymphoma cell lines (MUTU-I and DG-75).
Author: Byrne, Andrew J.
Qualification name:Doctor of Philosophy (Ph.D.)
Publisher:Trinity College (Dublin, Ireland). School of Pharmacy & Pharmaceutical Sciences
Note:TARA (Trinity’s Access to Research Archive) has a robust takedown policy. Please contact us if you have any concerns: email@example.com
Type of material:thesis
Availability:Full text available